



CONSOLIDATED FINANCIAL STATEMENTS

TERRABIOGEN TECHNOLOGIES INC.

(Expressed in Canadian Dollars)

FOR THE YEARS ENDED JUNE 30, 2017 AND 2016

INDEPENDENT AUDITORS' REPORT	1 - 2
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION	3
CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS	4
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY	5
CONSOLIDATED STATEMENTS OF CASH FLOWS	6
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS	7 - 23



KPMG LLP
PO Box 10426 777 Dunsmuir Street
Vancouver BC V7Y 1K3
Canada
Telephone 604-691-3000
Fax 604-691-3031

INDEPENDENT AUDITORS' REPORT

To the Shareholders of TerraBioGen Technologies Inc.

We have audited the accompanying consolidated financial statements of TerraBioGen Technologies Inc., which comprise the consolidated statements of financial position as at June 30, 2017 and June 30, 2016, the consolidated statements of loss and other comprehensive loss, changes in shareholders' equity and cash flows for the years then ended, and notes, comprising a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with International Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of consolidated statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with Canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained in our audits is sufficient and appropriate to provide a basis for our audit opinion.

KPMG LLP is a Canadian limited liability partnership and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative ("KPMG International"), a Swiss entity. KPMG Canada provides services to KPMG LLP.



Opinion

In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of TerraBioGen Technologies Inc. as at June 30, 2017 and June 30, 2016, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with International Financial Reporting Standards.

Emphasis of Matter

Without modifying our opinion, we draw attention to note 1 in the consolidated financial statements which indicates that TerraBioGen Technologies Inc. has a working capital deficiency, accumulated deficit and has incurred negative cash flows from operating activities. These conditions, along with other matters as set forth in note 1 in the consolidated financial statements, indicate the existence of a material uncertainty that may cast significant doubt about TerraBioGen Technologies Inc.'s ability to continue as a going concern.

KPMG LLP

Chartered Professional Accountants

October 27, 2017
Vancouver, Canada

TERRABIOGEN TECHNOLOGIES INC.
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

As at June 30, 2017 and 2016
(Expressed in Canadian Dollars)

	2017	2016
ASSETS		
Current Assets		
Cash	\$ 213,957	\$ 176,855
Amounts receivable (Note 6)	15,298	6,257
Inventory	23,610	4,829
Deposits and prepaid expenses (Note 7)	17,497	19,953
Total Current Assets	270,362	207,894
Property and equipment (Note 9)	115,990	179,977
Other assets	47,355	47,355
TOTAL ASSETS	\$ 433,707	\$ 435,226
LIABILITIES		
Current Liabilities		
Accounts payable and accrued liabilities (Note 8)	\$ 342,022	\$ 322,394
Total Current Liabilities	342,022	322,394
Provision for dismantling	6,447	6,251
TOTAL LIABILITIES	348,469	328,645
SHAREHOLDERS' EQUITY		
Share capital (Note 11)	40,478,088	39,656,113
Contributed surplus	2,842,421	2,405,759
Accumulated Deficit	(43,235,271)	(41,955,291)
TOTAL SHAREHOLDERS' EQUITY	85,238	106,581
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 433,707	\$ 435,226

Nature of Operations and Going Concern (Note 1)

Commitments (Note 16)

Subsequent Event (Note 18)

Signed on its behalf by:

"Blair Heffelfinger"
Director

"Theodore Deuel"
Director

The accompanying notes are an integral part of these consolidated financial statements.

TERRABIOGEN TECHNOLOGIES INC.
CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
For the Years Ended June 30, 2017 and 2016
(Expressed in Canadian Dollars)

	2017	2016
REVENUE		
Sale of products	\$ -	\$ 3,320
Other income	1,459	1,400
TOTAL REVENUE	1,459	4,720
EXPENSES		
Administration	621,435	456,400
Research and development, net (Note 15)	656,479	671,183
TOTAL EXPENSES	1,277,914	1,127,583
Loss before other items	(1,276,455)	(1,122,863)
Other items:		
Gain on sale of assets	-	3,733
Interest income	121	457
Interest expense	(3,646)	(2,714)
TOTAL OTHER ITEMS	(3,525)	1,476
NET LOSS AND COMPREHENSIVE LOSS	\$ (1,279,980)	\$ (1,121,387)
BASIC AND DILUTED LOSS PER COMMON SHARE	\$ (0.63)	\$ (0.60)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	2,020,707	1,865,303

The accompanying notes are an integral part of these consolidated financial statements.

TERRABIOGEN TECHNOLOGIES INC.
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
For the Years Ended June 30, 2017 and 2016
(Expressed in Canadian Dollars)

	Common Shares		Commitment to Issue Shares	Contributed Surplus	Accumulated Deficit	Total
	Number of Shares	Amount				
Balance at June 30, 2015	1,771,511	\$ 38,572,901	\$ 70,000	\$ 2,229,619	\$ (40,833,904)	\$ 38,616
Shares issued for cash	196,002	1,260,012	(70,000)	–	–	1,190,012
Issue of warrants	–	(176,140)	–	176,140	–	–
Share issue costs	–	(660)	–	–	–	(660)
Net loss for the year	–	–	–	–	(1,121,387)	(1,121,387)
Balance at June 30, 2016	1,967,513	\$ 39,656,113	\$ –	\$ 2,405,759	\$ (41,955,291)	\$ 106,581
Shares issued for cash	276,000	996,000	–	–	–	996,000
Issue of warrants	–	(174,025)	–	174,025	–	–
Stock based compensation	–	–	–	262,637	–	262,637
Net loss for the year	–	–	–	–	(1,279,980)	(1,279,980)
Balance at June 30, 2017	2,243,513	\$ 40,478,088	\$ –	\$ 2,842,421	\$ (43,235,271)	\$ 85,238

The accompanying notes are an integral part of these consolidated financial statements.

TERRABIOGEN TECHNOLOGIES INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Years Ended June 30, 2017 and 2016
(Expressed in Canadian Dollars)

	2017	2016
OPERATIONS		
Net loss	\$ (1,279,980)	\$ (1,121,387)
Items not involving cash:		
Depreciation (Note 9)	69,271	90,016
Gain on sale of assets	-	(3,733)
Share based compensation	262,637	-
Interest expense	3,646	2,714
Accretion on provision for dismantling	196	118
	(944,230)	(1,032,272)
Changes in non-cash working capital balances:		
Amounts receivable	(9,041)	12,189
Deposits and prepaid expenses	2,456	(3,340)
Inventory	(18,781)	(4,829)
Accounts payable and accrued liabilities	19,628	(14,731)
	(5,738)	(10,711)
Interest paid	(3,646)	(2,714)
CASH USED IN OPERATING ACTIVITIES	(953,614)	(1,045,697)
INVESTING		
Cash received on sale of assets	-	4,775
Purchase of property and equipment	(5,284)	(5,871)
CASH USED IN INVESTING ACTIVITIES	(5,284)	(1,096)
FINANCING		
Shares issued for cash (net of issue costs)	996,000	1,189,352
CASH PROVIDED BY FINANCING ACTIVITIES	996,000	1,189,352
Increase in cash	37,102	142,559
Cash, beginning of year	176,855	34,296
CASH, END OF YEAR	\$ 213,957	\$ 176,855

The accompanying notes are an integral part of these consolidated financial statements.

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended June 30, 2017 and 2016
(Expressed in Canadian Dollars)

1. NATURE OF OPERATIONS AND GOING CONCERN

TerraBioGen Technologies Inc. was incorporated in British Columbia, Canada, on August 17, 1993. The Company's common shares were traded on the TSX Venture Exchange until June 11, 2012 when they were delisted at the Company's request.

The Company has identified active ingredients that impart growth promotion and disease suppression in plants, and is planning to commercialize this technology. In recent years, the company has increased its research and development capabilities including a lab scale pilot line. The facility in Burnaby, BC is used exclusively for strain screening and development, product formulation, growth room and greenhouse trials, and production of materials for field trials.

These consolidated financial statements have been prepared on a going concern basis. At June 30, 2017, the Company had a working capital deficiency of \$71,660 (2016 - \$114,500), an accumulated deficit of \$43,235,271 (2016 - \$41,955,291), and a net cash outflow from operating activities of \$953,615 for the year then ended (2016 - \$1,045,697). These conditions indicate the existence of a material uncertainty which may cast significant doubt about the Company's ability to continue as a going concern. The Company's ability to continue its operations and to realize its assets' carrying values is dependent upon the continued support of its major shareholders (see Note 18), and ultimately, generating profitable operations and positive operating cash flows. Failure to obtain sufficient financing or other appropriate arrangements would require the Company's assets and liabilities to be restated on a liquidation basis which may differ significantly from the going concern basis. These consolidated financial statements do not give effect to any adjustments or disclosures which would be necessary should the Company be unable to continue as a going concern.

The address of the Company's corporate office and principal place of business is 8536 Baxter Place, Burnaby, BC V5A 4T8.

2. BASIS OF PREPARATION

Statement of Compliance

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS").

Approval of the Consolidated Financial Statements

The consolidated financial statements of the Company for the year ended June 30, 2017 were reviewed by the Audit Committee and approved and authorized for issuance by the Board of Directors on October 10, 2017.

Basis of Presentation

These consolidated financial statements have been prepared on the historical cost basis except for financial assets and financial liabilities that have been measured at fair value as described in Note 3. The accounting policies applied in these consolidated financial statements as described below, have been applied consistently to all periods presented as if the policies have always been in effect.

Use of estimates and judgements

The preparation of these consolidated financial statements requires management to make certain critical accounting estimates and assumptions that affect the application of accounting policies and the reported amount of assets, liabilities, income and expenses. It also requires management to exercise judgment in applying the Company's accounting policies. Significant areas requiring the use of management estimates include the fair value measurements for equity instruments and dismantling costs. Actual results could differ from those estimates.

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended June 30, 2017 and 2016
(Expressed in Canadian Dollars)

2. BASIS OF PREPARATION (continued)

Use of estimates and judgements (continued)

Information about assumptions and estimation uncertainties in applying accounting policies that have the most significant effect on the amounts recognized in the consolidated financial statements are included in the following notes:

- Note 11 Share capital – fair value measurements for equity instruments

Information about critical judgments that management has made in applying the Company's accounting policies that have the most significant effect on the amounts recognized in the consolidated financial statements include the going concern assessment, the applicability of government assistance programs, and the determination of segments and of cash generating units for purposes of impairment testing.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of consolidation - These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Genica Inc., which has been inactive since June 2012. All intercompany balances and transactions have been eliminated upon consolidation.

Revenue recognition – Revenue is recognized when the significant risks and rewards are transferred to the customers, persuasive evidence of the arrangement exists, the price is fixed and determinable and collection of the relevant receivable is probable, which is generally at the completion of the transaction. Revenue is measured at the fair value of the consideration received or receivable, net of returns and trade discounts.

Cash and cash equivalents – The Company considers all highly liquid investments with an original term to maturity of three months or less when acquired to be cash equivalents. Cash and cash equivalents are carried at amortized cost.

Property and equipment – Property and equipment are measured at historical cost less accumulated depreciation and any accumulated impairment losses. Cost includes expenditure that is directly attributable to the acquisition of the asset. Where the costs of certain components of an item of property and equipment are significant in relation to the total cost of an item and have different useful lives, they are accounted for and depreciated separately. Depreciation is determined based on the following annual rates:

Leasehold improvements	straight-line over lesser of useful life or initial lease term
Laboratory and plant equipment	20 - 30% declining balance
Office and computer equipment	20 - 30% declining balance
Mobile equipment	30% declining balance

The assets' useful lives and depreciation methods are reviewed, and adjusted prospectively if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals, if any, are determined by comparing the proceeds with the carrying amount and are recognized in the statements of loss and comprehensive loss.

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended June 30, 2017 and 2016
(Expressed in Canadian Dollars)

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Research and development – Research costs are expensed in the period incurred. Development costs are expensed in the period incurred unless the Company believes a development project meets specific criteria for capitalization. Development activities involve a plan or design for the production of new or substantially improved products and processes. Development costs are capitalized only if costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable and the Company intends to and has sufficient resources to complete development to use or sell the asset. Capitalized development costs are measured at cost less accumulated amortization and accumulated impairment losses. To date, no development costs have been capitalized.

Government assistance – Government grants are recognized and recorded as a reduction of research and development expenses where there is reasonable assurance that the grant will be received and all attaching conditions are met. Reimbursements of eligible costs pursuant to government corporate programs are recorded as a reduction of total costs when the related costs have been incurred and there is reasonable assurance regarding collection of the claim. Claims not settled by the statement of financial position date are recorded as a receivable on the statement of financial position. The determination of the amount of the claim, and hence the receivable amount, requires management to make calculations based on its interpretation of eligible expenditures in accordance with the terms of the programs. The reimbursement claims submitted by the Company are subject to review by the relevant government and corporate agencies. Although the Company has used its best judgment and understanding of the related program agreements in determining the receivable amount, it is possible that the amounts could increase or decrease by a material amount in the near term dependent on the review and audit by the government agency. Any funds received in advance of expenditures or eligibility requirements are recorded as deferred contributions on the statement of financial position and adjusted as subsequent claims are made by the Company.

If a grant becomes repayable, it will be treated as a change in estimate and recorded prospectively. Where the original grant is related to income, the repayment would be applied first against any related undepreciated deferred contributions, and any excess will be recognized as an expense.

Leases – Leases are classified as either finance or operating leases. Leases that transfer substantially all of the benefits and risks incidental to the ownership of equipment are classified as finance leases. At the inception of a finance lease, the equipment and an obligation is recorded at the lower of its fair value and the present value of the minimum lease payments. Equipment under a finance lease is depreciated on a declining-balance basis at rates varying from 20 to 30% per annum, which approximates the equipment's estimated useful life. Minimum lease payments made under finance leases are apportioned between the finance expense and the reduction of the outstanding liability. The finance expense is allocated to each period during the lease term so as to produce a constant periodic rate of interest on the remaining liability.

All other leases are classified as operating leases. Payments made under operating leases are recognized in income on a straight-line basis over the term of the lease. Lease incentives received are recognized as a reduction to the lease expense over the term of the lease.

Provisions - A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risk specific to the liability. The unwinding of the discount is recognized as a finance cost.

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended June 30, 2017 and 2016
(Expressed in Canadian Dollars)

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Decommissioning provisions – The Company’s activities give rise to dismantling, decommissioning and site disturbance re-remediation activities. A provision is made for the estimated cost of site restoration and capitalized in the relevant asset category.

Decommissioning provisions are measured at the present value of management’s best estimate of expenditure required to settle the present obligation at the statement of financial position date. Subsequent to initial measurement, the obligation is adjusted at the end of each period to reflect the passage of time and changes in the estimated future cash flows underlying the obligation. The increase in the provision due to the passage of time is recognized as finance costs whereas increases/decreases due to changes in the estimated future cash flows are recorded against the related asset. Actual costs incurred upon settlement of the decommissioning provisions are charged against the provision to the extent the provision was established.

Impairment – The carrying amounts of the Company’s property and equipment are reviewed at each reporting date for indicators of impairment. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the amount of the impairment, if any. The recoverable amount of an asset is evaluated at the cash generating unit level (“CGU”), which is the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or group of assets. The recoverable amount of an asset or CGU is the greater of its fair value less costs to sell and its value in use. Fair value is determined as the amount that would be obtained from the sale of the asset in arm’s length transaction between knowledgeable and willing parties, less the costs of disposal. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. An impairment loss is recognized if the carrying amount of an asset or its CGU exceeds its estimated recoverable amount. Impairment losses are recognized in profit or loss. Impairment losses recognized in respect of CGU’s are allocated to reduce the carrying amounts of the other assets in the unit (group of units) on a pro rata basis.

Impairment losses recognized in prior years are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation, if no impairment loss had been recognized.

Income taxes - Income tax expense comprises current tax expense and deferred tax expense. Current and deferred taxes are recognized as an expense and included in income or loss for the period, except to the extent that the tax arises from a transaction which is recognized in other comprehensive income or directly in equity.

Current tax expense is the amount of income taxes payable (recoverable) in respect of the taxable income (tax loss) for a period. Current liabilities (assets) for the current and prior periods are measured at the amount expected to be paid to (recovered from) the taxation authorities, using the tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax assets and liabilities are recognized for temporary differences which are differences between the carrying amount of an asset or liability in the statement of financial position and its tax base, the carry-forward of unused tax losses and unused tax credits. Deferred tax assets and liabilities are measured at the tax rate that is expected to apply when the asset is realized or the liability is settled, based on tax rates that have been enacted or substantively enacted by the end of the reporting period. Deferred tax assets are recognized for unused tax losses, tax credits, and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be utilized.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended June 30, 2017 and 2016
(Expressed in Canadian Dollars)

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Share-based compensation – The Company provides an incentive stock option plan. Share-based payments to employees are measured at the fair value of the instruments issued and amortized over the vesting periods. Share-based payments to non-employees are measured at the fair value of goods or services received or the fair value of the equity instruments issued, if it is determined the fair value of the goods or services cannot be reliably measured, and are recorded at the date the goods or services are received. The fair value of share-based compensation is charged to the statement of loss and comprehensive loss with a corresponding credit recorded to contributed surplus. The fair value of options is determined using a Black-Scholes option pricing model. The number of shares and options expected to vest is reviewed and adjusted at the end of each reporting period such that the amount recognized for services received as consideration for the equity instruments granted shall be based on the number of equity instruments that eventually vest.

Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options, measured immediately before and after the modification, is also charged to the statement of loss and comprehensive loss over the remaining vesting period.

The Black-Scholes option pricing model requires management to make estimates, which are subjective and may not be representative of actual results. Changes in assumptions can materially affect estimates of fair values.

Share capital – Common shares issued by the Company are classified as equity. Costs directly attributable to the issue of common shares, share purchase warrants and share options are recognized as a deduction from equity. Equity instruments issued to agents are considered share issue costs and are measured at their fair value at the date of grant.

Foreign currency translation – The functional currency of the Company, being the currency of the primary economic environment in which the Company operates, is the Canadian dollar. Foreign denominated monetary assets and liabilities are translated at the period-end rates of exchange. Non-monetary assets and liabilities are translated using the exchange rates prevailing at the date of the transaction. Revenues and expenses are translated using average rates of exchange during the year. Exchange gains or losses arising from currency translation are recognized in the statement of loss and comprehensive loss.

Earnings (loss) per common share – Basic earnings (loss) per common share is computed by dividing the net income or loss applicable to common shares of the Company by the weighted average number of common shares outstanding for the relevant period.

Diluted earnings (loss) per common share is computed by dividing the net income or loss applicable to common shares by the sum of the weighted average number of common shares issued and outstanding and all additional common shares that would have been outstanding, if potentially dilutive instruments were converted. This follows the treasury stock method in which the dilutive effect on loss per share is recognized based on the proceeds that could be obtained from the exercise of options, warrants, and similar instruments. As at June 30, 2017, 177,000 share options (2016 – 5,000) and 869,125 warrants (2016 – 593,125) were excluded from the diluted weighted average number of ordinary shares calculation because their effect would have been anti-dilutive.

Financial instruments – All financial assets are initially recorded at fair value and designated upon inception into one of the following four categories: held to maturity, available-for-sale, loans and receivables or at fair value through profit or loss (“FVTPL”). The Company derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or when it transfers substantially all the risks and rewards of ownership of the financial asset.

Financial assets classified at fair value through profit or loss are measured at fair value with unrealized gains and losses recognized through profit or loss. At June 30, 2017, the Company has not classified any financial assets as FVTPL.

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended June 30, 2017 and 2016
(Expressed in Canadian Dollars)

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Financial instruments (continued)

Financial assets classified as loans and receivables and held to maturity are measured at amortized cost using the effective interest method, less any impairment losses. Cash and accounts receivable are classified as loans and receivables.

Financial assets classified as available-for-sale are measured at fair value with unrealized gains and losses recognized in other comprehensive income except for impairment losses which are recognized in profit and loss. At June 30, 2017, the Company has not classified any financial assets as available-for-sale.

Transaction costs associated with financial assets classified at fair value through profit or loss are expensed as incurred, while transaction costs associated with all other financial assets are included in the initial carrying amount of the asset.

Financial assets not carried at fair value through profit or loss are assessed at each reporting date to determine whether there is objective evidence that it is impaired. Financial assets are impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset, and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably.

An impairment loss in respect of a financial asset measured at amortized cost is calculated as the difference between its carrying amount and the present value of the estimated future cash flows discounted at the asset's original effective interest rate. Losses are recognized in profit or loss and reflected in an allowance account against receivables. Interest on the impaired asset continues to be recognized through the unwinding of the discount. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss.

Financial liabilities are initially recognized on the date they are originated and are derecognized when the contractual obligations are discharged or cancelled or expire. All financial liabilities are initially recorded at fair value and designated upon inception at fair value through profit or loss or other financial liabilities.

Financial liabilities classified as other financial liabilities are measured at amortized cost, using the effective interest method, when materially different from the initial amount. Fair value is determined based on the present value of future cash flows, discounted at the market rate of interest. Accounts payable and accrued liabilities are classified as other financial liabilities.

Financial liabilities classified at fair value through profit or loss are measured at fair value with unrealized gains and losses recognized through profit or loss. At June 30, 2017, the Company has not classified any financial liabilities at fair value through profit or loss.

Segment reporting policy - An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Company's other components. Segment results include items directly attributable to a segment as well as those that can be allocated on a reasonable basis. Unallocated items comprise mainly corporate assets, head office expenses, and income tax assets and liabilities. The Company operates in one segment which encompasses the research and development to identify and characterize the active ingredients in its products and corporate activities to support research and development. All of the Company's property and equipment is located in Canada.

Comparative figures - Certain comparative figures have been reclassified to conform with the financial statement presentation adopted for the current year.

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended June 30, 2017 and 2016
(Expressed in Canadian Dollars)

4. NEW ACCOUNTING PRONOUNCEMENTS
New standards and interpretations not yet adopted

The following is an overview of accounting standard changes that the Company will be required to adopt in future years. The Company does not expect to adopt any of these standards before their effective dates. The Company continues to evaluate the impact of these standards on its consolidated financial statements.

(a) Clarification of Acceptable Methods of Depreciation and Amortization (Amendments to IAS 16 and IAS 38)

On May 12, 2014 the IASB issued amendments to IAS 16 Property, Plant and Equipment and IAS 38 Intangible Assets. The amendments made to IAS 16 explicitly state that revenue-based methods of depreciation cannot be used for property, plant and equipment. This is because such methods reflect factors other than the consumption of economic benefits embodied in the asset. The amendments in IAS 38 introduce a rebuttable presumption that the use of revenue-based amortization methods for intangible assets is inappropriate. This presumption could be overcome only when revenue and consumption of the economic benefits of the intangible asset are highly correlated or when the intangible asset is expressed as a measure of revenue.

The Company intends to adopt the amendments to IAS 16 and IAS 38 in its consolidated financial statements for the annual period beginning on July 1, 2017. The Company does not expect the amendments to have a significant impact on the consolidated financial statements.

(b) IFRS 9 - Financial Instruments:

On July 24, 2014 the IASB issued the complete IFRS 9 (IFRS 9 (2014)).

IFRS 9 (2014) introduces new requirements for the classification and measurement of financial assets. Under IFRS 9 (2014), financial assets are classified and measured based on the business model in which they are held and the characteristics of their contractual cash flows.

The standard introduces additional changes relating to financial liabilities.

It also amends the impairment model by introducing a new 'expected credit loss' model for calculating impairment.

IFRS 9 (2014) also includes a new general hedge accounting standard which aligns hedge accounting more closely with risk management.

The mandatory effective date of IFRS 9 is for annual periods beginning on or after January 1, 2018 and must be applied retrospectively with some exemptions. Early adoption is permitted. The restatement of prior periods is not required and is only permitted if information is available without the use of hindsight.

The Company intends to adopt IFRS 9 (2014) in its financial statements for the annual period beginning on July 1, 2018. The extent of the impact of adoption of the standard has not yet been determined.

(c) IFRS 15 Revenue from Contracts with Customers

On May 28, 2014 the IASB issued IFRS 15 Revenue from Contracts with Customers. The new standard is effective for annual periods beginning on or after January 1, 2017. On July 22, 2015, the IASB deferred the effective date of this standard to January 1, 2018 with earlier adoption permitted.

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended June 30, 2017 and 2016
(Expressed in Canadian Dollars)

4. NEW ACCOUNTING PRONOUNCEMENTS (continued)

(c) IFRS 15 Revenue from Contracts with Customers (continued)

The standard contains a single model that applies to contracts with customers and two approaches to recognising revenue: at a point in time or over time. The model features a contract-based five-step analysis of transactions to determine whether, how much and when revenue is recognized. New estimates and judgmental thresholds have been introduced, which may affect the amount and/or timing of revenue recognized.

The Company intends to adopt IFRS 15 in its financial statements for the annual period beginning on July 1, 2018. The extent of the impact of adoption of the standard has not yet been determined.

(d) IFRS 16 Leases

In January 2016, the IASB issued IFRS 16 – Leases, which supersedes IAS 17 – Leases. IFRS 16 establishes principals for the recognition, measurements presentation and disclosure of leases. The standard establishes a single model for lessees to bring leases on balance sheet while lessor accounting remains largely unchanged and retains the finance and operation lease distinctions. IFRS 16 is effective for annual periods beginning on or after January 1, 2019 with earlier adoption permitted, but only if also applying IFRS 15 – Revenue from Contracts with Customers. The Company is currently evaluating the impact of IFRS 16 on its financial statements.

5. FINANCIAL INSTRUMENTS

The Company's financial instruments consist of cash, amounts receivable and accounts payable and accrued liabilities.

Fair value

The Company classifies its fair value measurements in accordance with an established hierarchy that prioritizes the inputs in valuation techniques used to measure fair value as follows:

Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities

Level 2 – inputs other than quoted prices included in Level 1 that are observable for the assets or liabilities, either directly (i.e. as prices) or indirectly (i.e. from derived prices); and

Level 3 – inputs for the asset or liability that are not based upon observable market data

The Company believes the recorded values of all financial instruments approximate their current fair values because of their nature and short term maturity dates.

Foreign exchange risk

Most of the Company's operating expenditures are denominated in Canadian dollars and certain operating expenses are in United States dollars. The Company's exposure to foreign currency risk arises primarily on fluctuations between the Canadian dollar and the United States dollar.

The Company has not entered into any derivative instruments to manage foreign exchange fluctuations.

At June 30, 2017 and June 30, 2016, a change of 10% +/- in the US dollar would not result in a significant impact in the statements of loss and comprehensive loss.

Interest rate risk

The Company is subject to interest on its bank loans which are at negotiated rates of interest. Significant increase in these interest rates would result in increased costs for the Company.

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended June 30, 2017 and 2016
(Expressed in Canadian Dollars)

5. FINANCIAL INSTRUMENTS (continued)

Credit risk

Credit risk is the risk of an unexpected loss if a counterparty to a financial instrument fails to meet its contractual obligations. The credit risk associated with cash is believed to be minimal as cash is on deposit with Canadian banks that are believed to be creditworthy. Amounts receivable is comprised primarily of amounts due from the Government of Canada. The Company does not believe it is exposed to significant credit risk.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company manages liquidity risk through the management of its capital structure and financial leverage as outlined above.

The Company monitors its ability to meet its short-term operating expenditures by raising additional funds through share issuances when required.

6. AMOUNTS RECEIVABLE

		2017		2016
Goods and Services Tax	\$	15,102	\$	6,257
Other		196		-
	\$	15,298	\$	6,257

7. DEPOSITS AND PREPAID EXPENSES

		2017		2016
Prepaid insurance premiums	\$	9,819	\$	7,378
Other		7,678		12,575
	\$	17,497	\$	19,953

8. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

		2017		2016
Trade payables	\$	60,690	\$	49,600
Accrued liabilities		33,218		21,634
Vacation payable		8,296		18,052
Salaries payable		29,818		23,107
Customer deposits		210,000		210,000
	\$	342,022	\$	322,394

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended June 30, 2017 and 2016
(Expressed in Canadian Dollars)

9. PROPERTY AND EQUIPMENT

	2017				Total
	Laboratory and plant equipment	Mobile equipment	Leasehold improvements	Office and computer equipment	
Costs					
Balance, July 1, 2016	\$ 656,237	\$ 12,115	\$ 97,349	\$ 192,226	\$ 957,927
Additions	5,284	-	-	-	5,284
Balance, June 30, 2017	\$ 661,521	\$ 12,115	\$ 97,349	\$ 192,226	\$ 963,211
Accumulated depreciation					
Balance July 1, 2016	\$ 511,175	\$ 8,584	\$ 75,450	\$182,741	\$777,950
Depreciation	43,935	1,060	21,899	2,377	69,271
Balance, June 30, 2017	\$ 555,110	\$ 9,644	\$ 97,349	\$185,118	\$847,221
Carrying amount at June 30, 2017	\$ 106,411	\$ 2,471	-	\$ 7,108	\$ 115,990
	2016				Total
	Laboratory and plant equipment	Mobile equipment	Leasehold improvements	Office and computer equipment	
Costs					
Balance, July 1, 2015	\$ 652,259	\$ 12,115	\$ 97,349	\$ 192,226	\$ 953,949
Additions	5,871	-	-	-	5,871
Disposals	(1,893)	-	-	-	(1,893)
Balance, June 30, 2016	\$ 656,237	\$ 12,115	\$ 97,349	\$ 192,226	\$ 957,927
Accumulated depreciation					
Balance July 1, 2015	\$ 451,785	\$ 7,070	\$ 50,417	\$179,513	\$688,785
Disposals	(851)	-	-	-	(851)
Depreciation	60,241	1,514	25,033	3,228	90,016
Balance, June 30, 2016	\$ 511,175	\$ 8,584	\$ 75,450	\$182,741	\$777,950
Carrying amount at June 30, 2016	\$ 145,062	\$ 3,531	\$ 21,899	\$ 9,485	\$ 179,977

Total depreciation expense for the year ended June 30, 2017 was \$69,271 (2016 - \$90,016), \$25,335 (2016 - \$29,775) is allocated to administration, and \$43,936 (2016 - \$60,241) is allocated to research and development).

10. CREDIT FACILITY

The Company has a loan agreement with HSBC Bank Canada under a credit facility. The credit facility consists of a \$100,000 operating loan which bears interest at the bank's prime rate plus 1.25% per annum and is payable on demand. The loan is secured by a general security agreement providing a first security interest in all of the Company's assets and ranks ahead of all other loans. As at June 30, 2017 and June 30, 2016, the Company had no outstanding drawings against this credit facility.

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended June 30, 2017 and 2016
(Expressed in Canadian Dollars)

11. SHARE CAPITAL

Authorized Share Capital

The Company has authorized share capital of an unlimited number of common shares without par value and an unlimited number of preferred shares without par value. There have been no preferred shares issued as at June 30, 2017 and 2016.

Issued and outstanding: See Statement of Changes in Equity.

The following share transactions have occurred:

- a) On July 13, 2015, the Company issued 42,000 units at \$10.00 per unit for gross proceeds of \$420,000. Each unit consists of one common share and one warrant exercisable at \$12.00 per share until July 12, 2020.
- b) On December 29, 2015, the Company issued 84,000 units at \$5.00 per unit for gross proceeds of \$420,000. Each unit consists of one common share and one warrant exercisable at \$6.00 per share until December 28, 2020.
- c) On May 6, 2016, the Company issued 70,002 units at \$6.00 per unit for gross proceeds of \$420,012. Each unit consists of one common share and one warrant exercisable at \$7.50 per share until May 5, 2021.
- d) On January 24, 2017, the Company issued 84,000 units at \$5.00 per unit for gross proceeds of \$420,000. Each unit consists of one common share and one warrant exercisable at \$6.00 per share until January 23, 2022.
- e) On May 30, 2017, the Company issued 192,000 units for gross proceeds of \$576,000. Each Unit consists of one common share and one warrant exercisable at \$5.00 per share expiring until May 29, 2022.

Warrants – Details of share purchase warrants during the periods ended June 30, 2017 and 2016 are as follows:

	2017		2016	
	Number	Weighted Average Exercise Price \$	Number	Weighted Average Exercise Price \$
Outstanding, beginning of year	593,125	10.62	397,123	12.00
Issued	276,000	5.30	196,002	7.82
Expired	-	-	-	-
Outstanding, end of year	869,125	8.93	593,125	10.62

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended June 30, 2017 and 2016
(Expressed in Canadian Dollars)

11. SHARE CAPITAL (continued)

As at June 30, 2017, the Company had share purchase warrants outstanding and exercisable as follows:

Number of Warrants Outstanding and Exercisable		Exercise Price per Share	Expiry Date	Weighted average Remaining Life
June 30, 2017	June 30, 2016			
90,000	90,000	\$12.00	March 6, 2018	0.69 years
46,000	46,000	\$12.00	May 31, 2018	0.92 years
43,000	43,000	\$12.00	Sept. 5, 2018	1.19 years
42,000	42,000	\$12.00	Oct. 24, 2018	1.32 years
8,123	8,123	\$12.00	Oct. 30, 2018	1.34 years
21,000	21,000	\$12.00	Jan. 22, 2019	1.57 years
21,000	21,000	\$12.00	April 24, 2019	1.82 years
21,000	21,000	\$12.00	June 10, 2019	1.95 years
21,000	21,000	\$12.00	Sept. 8, 2019	2.19 years
42,000	42,000	\$12.00	Dec. 28, 2019	2.50 years
42,000	42,000	\$12.00	Feb. 18, 2020	2.64 years
42,000	42,000	\$12.00	July 12, 2020	3.04 years
84,000	84,000	\$6.00	Dec. 28, 2020	3.50 years
70,002	70,002	\$7.50	May 5, 2021	3.85 years
84,000	-	\$6.00	Jan. 23, 2022	4.57 years
192,000	-	\$5.00	May 29, 2022	4.92 years
869,125	593,125			3.01 years

The Company uses the Black-Scholes pricing model to estimate the fair value of share purchase warrants. The fair value of the warrants as estimated using the Black-Scholes pricing model also considers a discount factor due to the lack of liquidity of the warrants. The model requires management to make estimates which are subjective and may not be representative of actual results. Changes in assumptions can materially affect estimates of fair values. For purposes of the calculation, the following weighted average assumptions were used:

	<u>2017</u>	<u>2016</u>
Risk-free interest rate	0.99%	0.75%
Expected dividend yield	0%	0%
Expected stock price volatility	67%	49%
Expected life of warrants	5.00 years	5.00 years

The weighted average fair value of the warrants issued during the period was \$0.75 (2016 - \$0.90).

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended June 30, 2017 and 2016
(Expressed in Canadian Dollars)

11. SHARE CAPITAL (continued)

Stock options

The Company grants stock options to directors, officers, employees and consultants as compensation for services, pursuant to its Incentive Stock Option Plan (the "Plan") instituted in 1999 and amended, most recently in November 2016. Options issued pursuant to the Plan have an exercise price as determined by the Board. Options have a maximum expiry period of ten (2016 – five) years from the grant date. The number of options, which may be issued under the plan, is limited to no more than 10% of the Company's issued and outstanding shares on the grant date. The aggregate number of options granted to any one optionee in a twelve-month period is limited to 5% of the Company's issued shares at the time the options are granted. Options granted under the plan are subject to vesting terms determined by the Board. All options are to be settled by the physical delivery of shares. Only optionees who remain in service to the Company shall be entitled to purchase shares.

A summary of the Company's share options at June 30, 2017 and 2016 and the changes for the year ended on those dates is presented below:

	2017		2016	
	Options Outstanding	Weighted Average Exercise Price	Options Outstanding	Weighted Average Exercise Price
Opening balance	5,000	\$12.00	38,000	\$12.00
Forfeited or expired	(5,000)	(12.00)	(33,000)	(12.00)
Granted	177,000	5.00	-	-
Ending balance	177,000	\$5.00	5,000	\$12.00

The Company had the following share options outstanding and exercisable:

June 30, 2017					
Quantity		Exercise		Vesting Conditions	Weighted Average Remaining Life
Outstanding	Exercisable	Price	Expiry Date		
90,000	90,000	\$5.00	Mar 20, 2027	Vested immediately	9.73 years
87,000	87,000	\$5.00	May 23, 2027	Vested immediately	9.90 years
177,000	177,000				9.81 years

The Company uses the Black-Scholes pricing model to estimate the fair value of stock options. The fair value of the stock options as estimated using the Black-Scholes pricing model also considers a discount factor due to the lack of liquidity of the stock options. The model requires management to make estimates which are subjective and may not be representative of actual results. Changes in assumptions can materially affect estimates of fair values. For purposes of the calculation, the following weighted average assumptions were used:

	<u>2017</u>	<u>2016</u>
Risk-free interest rate	1.57%	-
Expected dividend yield	0%	-
Expected stock price volatility	86%	-
Expected life of warrants	10 years	-

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended June 30, 2017 and 2016
(Expressed in Canadian Dollars)

The weighted average contractual life remaining on the above options is 9.81 years (June 30, 2016 – 0.26 years).

Total share-based compensation for the years ended June 30, 2017 was \$262,637 (2016 – Nil).

12. RELATED PARTY TRANSACTIONS AND KEY MANAGEMENT PERSONNEL

As of June 30, 2017 and June 30, 2016, the Company has identified its directors and senior officers as its key management personnel and the compensation costs for key management personnel and companies related to them were recorded at their exchange amounts as agreed upon by the transacting parties.

The compensation costs for key management personnel for the year ended June 30, 2017 and June 30, 2016 are as follows:

	2017	2016
Salaries and benefits	\$ 473,175	\$ 268,860
	\$ 473,175	\$ 268,860

Other related party transactions during the year ended June 30, 2017:

- a) Consulting fees of \$4,000 (2016 - \$48,000) were expensed for services provided by a company controlled by an officer.
- b) Accounts payable and accrued expenses include fees payable to directors of \$5,800 (2016 - \$3,800). Fees to directors of \$11,600 (2016 - \$10,000) were expensed during the year, and fees of \$9,600 (2016 - \$10,200) were paid to directors during the year.

13. PERSONNEL EXPENSES

Personnel expenses are included in administration and research and development as follows:

	2017	2016
Administration	\$ 193,485	\$ 171,912
Research and development	352,646	351,950
	\$ 546,131	\$ 523,862

14. INCOME TAXES

a) The reconciliation of income tax computed at statutory rates to income tax expense, using a 26% (2016 – 26%) statutory rate is:

	2017	2016
Income (loss) before income taxes	\$ (1,279,980)	(1,121,387)
Statutory rate	26%	26%
Tax expense (recovery) at statutory income tax rates	(332,795)	(291,561)
Reconciliation of effective tax rate:		
Permanent differences and other	(73,691)	(172)
Change in unrecognized temporary differences	253,346	436,910
True-up prior year	5,758	(145,177)

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended June 30, 2017 and 2016
(Expressed in Canadian Dollars)

Income tax expense	\$	-	\$	-
--------------------	----	---	----	---

14. INCOME TAXES (continued)

b) Unrecognized deferred tax assets:

Deferred tax assets have not been recognized in respect of the following items because it is not probable that future taxable profit will be available against which the Company can use the benefits therefrom.

	June 30, 2017		June 30, 2016	
Non-capital losses	\$ 12,090,486		\$ 11,738,452	
Property and equipment	8,759,126		8,689,875	
SRED	7,276,708		6,729,938	
Accrued liabilities and other	6,932		-	
Share issuance costs	880		1,459	
	\$ 28,134,131		\$ 27,159,724	

Non-capital losses – At June 30, 2017, the Company has tax losses of approximately \$12,090,486 (2016 - \$11,738,452) available to offset future taxable income. These non-capital loss carryforwards begin to expire in 2027.

Scientific research and experimental development costs (“SRED”) - The Company has SRED costs of \$7,276,708 (2016 - \$6,729,938) available to offset future taxable income, expiring indefinitely.

The application of non-capital losses and SRED against future taxable income is subject to final determination by the Canada Revenue Agency.

As at June 30, 2017, the Company has approximately \$1,770,000 of investment tax credits (2016 - \$1,589,000) available to reduce taxes payable in future years. The investment tax credits have not been recognized as it is not probable that future taxes payable will be available against which the Company can use the benefits therefrom.

15. GOVERNMENT ASSISTANCE

The Company receives government assistance under a number of government programs. Under these programs, the Company had signed contribution agreements with a maximum contribution of \$153,300 and expiry dates ranging from August 31, 2017 to November 30, 2017. In the year ended June 30, 2017, the Company filed claims for \$62,425 and all of these amounts have been received. The Company anticipates that it will claim the full remaining contribution amount of \$90,875.

16. COMMITMENTS

In the year ended June 30, 2013, the Company signed a lease for premises located in Burnaby, British Columbia. The lease was renewed for an additional four-year term in May 2017. The future minimum lease payments is as follows:

2018			91,125	
2019			91,406	
2020			94,500	

TERRABIOGEN TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended June 30, 2017 and 2016
(Expressed in Canadian Dollars)

2021

86,625

The Company paid a security deposit of \$7,612 which will be applied against the final month's rent.

17. CAPITAL MANAGEMENT

The Company manages its capital structure in order to ensure sufficient resources are available to meet operational requirements. The Company manages the components of shareholders' equity and its liabilities including its bank line of credit as capital, and makes adjustments to these components in response to the Company's business objectives and the economic climate. To maintain or adjust its capital structure, the Company may attempt to issue new common shares from treasury, issue debt instruments or borrow money.

The Company expects its current capital resources, together with the proceeds from planned additional equity fundraising, will be sufficient to carry out its operations through its next operating period.

The Company does not anticipate the payment of dividends in the foreseeable future.

18. SUBSEQUENT EVENT

Subsequent to June 30, 2017, the Company closed a non-brokered private placement of 192,000 units at \$3.00 per unit for gross proceeds of \$576,000. Each unit consists of one common share and one warrant exercisable at \$5.00 per share expiring in five years.



TERRABIOGEN TECHNOLOGIES INC.

MANAGEMENT DISCUSSION & ANALYSIS

For the year ended June 30, 2017

**TERRABIOGEN TECHNOLOGIES INC.
MANAGEMENT DISCUSSION AND ANALYSIS
FOR THE YEAR ENDED JUNE 30, 2017**

This discussion and analysis of financial position and results of operations is prepared as at October 30, 2017. The Management's Discussion and Analysis ("MD&A") should be read in conjunction with the audited consolidated financial statements of TerraBioGen Technologies Inc. (the "Company") as at and for the year ended June 30, 2017 and related notes thereof which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board. Except as otherwise disclosed, all dollar figures included therein and the following MD&A are quoted in Canadian dollars. Additional information relevant to the Company's activities can be found on SEDAR at www.sedar.com or the Company's website at www.terrabiogen.com.

Forward Looking Statements

Certain information included in this discussion may constitute forward-looking statements. Forward-looking statements are based on current expectations and entail various risks and uncertainties. These risks and uncertainties could cause or contribute to actual results that are materially different than those expressed or implied. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "plan," "intend" or "project" or the negative of these words or other variations on these words or comparable terminology. Readers are cautioned regarding statements discussing profitability; growth strategies; anticipated trends in our industry; our future financing plans; and our anticipated needs for working capital.

While it is impossible to identify all such factors, factors that could cause actual results to differ materially from those estimated by us include: inability or delays in achieving its technical development and commercialization milestones, environmental factors that could impact the Company's product field trial performance, delays in achieving regulatory approval of its products, inability or delays in securing the necessary funding to complete the development and commercialization of its products.

The Company disclaims any obligation or intention to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required to do so by law.

Description of the Business

TerraBioGen Technologies Inc. was incorporated in British Columbia, Canada, on August 17, 1993. The Company's common shares were traded on the TSX Venture Exchange until June 11, 2012 when they were delisted at the Company's request.

The Company has developed microbial metabolite bioactive materials that improve plant health and yield, and impart biotics and abiotic stress tolerance in plants. The Company is in the process of commercializing this technology. In recent years, the company has increased its research and development capabilities including a lab scale pilot line. The facility in Burnaby, BC is used exclusively for strain screening and development, product formulation, growth room and greenhouse trials, and production of materials for field trials and commercialization.

The Company is committed to research and development to continue to improve the effectiveness of its technologies, the quality of its products, and the creation of new product lines. Through collaborations with some of the leading agricultural institutes in North America and funding from Canadian national and provincial government programs, TerraBioGen is developing and testing microbial derived bioactive materials that are responsible for the improved crop yields and increase stress tolerance in a wide range of plant varieties. Further, the Company is taking steps to secure intellectual property rights to these bioactive materials and to formulate them in order to fully commercialize their potential.

**TERRABIOGEN TECHNOLOGIES INC.
MANAGEMENT DISCUSSION AND ANALYSIS
FOR THE YEAR ENDED JUNE 30, 2017**

Overall Performance

The Company is a development company with minimal revenues to date from its activities.

The following selected annual financial information is derived from the audited consolidated financial statements of the Company prepared in accordance with IFRS.

Year ended June 30	2017	2016	2015
Revenues	\$ 1,459	\$ 4,720	\$ 94
Loss before other income (expense)	(1,276,455)	(1,122,863)	(1,149,630)
Net finance income (expense)	(3,525)	(2,257)	(2,371)
Gain on sale of assets	-	3,733	-
Net loss	(1,279,980)	(1,121,387)	(1,152,001)
Net loss per share (basic and diluted)	\$ (0.63)	\$ (0.60)	\$ (0.67)
Total assets	\$ 433,707	\$ 435,226	\$ 381,874
Long term liabilities	6,447	6,251	6,133

Quarterly Financial Results

	Year ended June 30, 2017				Year ended June 30, 2016			
	Apr- Jun/17 Q4 2017	Jan- Mar/17 Q3 2017	Oct- Dec/16 Q2 2017	Jul- Sep/16 Q1 2017	Apr- Jun/16 Q4 2016	Jan- Mar/16 Q3 2016	Oct- Dec/15 Q2 2016	Jul- Sep/15 Q1 2016
Revenues	\$ 1,459	\$ -	\$ -	\$ -	\$ -	\$ 1,219	\$ 3,501	\$ -
Loss before other income (expense)	(537,241)	(258,652)	(282,194)	(198,247)	(318,686)	(277,228)	(275,113)	(251,836)
Net finance expense	(718)	(838)	(787)	(1,303)	(532)	(752)	(553)	(420)
Gain/loss on sale of assets	-	-	-	-	140	3,685	(92)	-
Net Loss	(537,959)	(259,490)	(282,981)	(199,550)	(319,078)	(274,295)	(275,758)	(252,256)
Net Loss per share (basic and diluted)	\$ (0.26)	\$ (0.13)	\$ (0.14)	\$ (0.10)	\$ (0.16)	\$ (0.15)	\$ (0.15)	\$ (0.14)
	June 30/17	Mar. 31/17	Dec. 31/16	Sept. 30/16	June 30/16	Mar. 31/16	Dec. 31/15	Sept. 30/15
Total assets	\$ 433,707	\$ 358,131	\$ 209,513	\$ 237,509	\$ 435,226	\$ 289,626	\$ 585,932	\$ 441,346
Long term liabilities	6,447	6,407	6,368	6,329	6,251	6,251	6,211	6,172

Comparison of the year ended June 30, 2017 to the year ended June 30, 2016

The Company recorded revenue of \$1,459 primarily from government hiring incentives in the year ending June 30, 2017. During the prior year, the Company recorded revenue of \$4,720 including \$3,320 from the sale of products.

During the year ended June 30, 2017, the Company recorded total expenses of \$1,277,914, compared to \$1,127,583 in the prior year, an increase of \$150,331. Administration costs increased by \$165,035, and research and development costs decreased by \$14,704.

The majority of the administration cost increase was due to \$219,309 in stock based compensation resulting from the award of 132,500 stock options, partially offset by decreases of \$22,427 in wages and management fees and \$26,482 in travel costs. The research and development decrease was largely due to a \$25,095 decrease in the use of contractors and a \$24,220 increase in government funding, which were partially offset by \$43,328 in stock based compensation resulting from the award of 44,500 stock options.

During the year ended June 30, 2017, the Company incurred interest expense of \$3,646 and earned interest income of \$121, resulting in a net loss for the year of \$1,279,980 or \$0.63 per share. In the previous year, the Company incurred interest expense of \$2,714 and earned interest income of \$457, and realized a gain of \$3,733 on the sale of assets, resulting in a net loss of \$1,121,387 or \$0.60 per share.

**TERRABIOGEN TECHNOLOGIES INC.
MANAGEMENT DISCUSSION AND ANALYSIS
FOR THE YEAR ENDED JUNE 30, 2017**

Comparison of the three months ended June 30, 2017 to the three months ended June 30, 2016

There was no revenue recorded in either of the three months ending June 30, 2017 or June 30, 2016.

During the three months ended June 30, 2017, the Company recorded total expenses of \$538,807, compared to \$319,083 in the prior year, an increase of \$219,724. Administration costs increased by \$194,168 and research and development costs increased by \$25,556; in both departments, the grant of stock options was the primary reason for the increases.

During the three months ended June 30, 2017, the Company received income of \$1,459 primarily from government hiring incentives, incurred interest expense of \$717 and earned interest income of \$107, resulting in a net loss for the three months of \$537,959 or \$0.26 per share. In the previous year, the Company incurred interest expense of \$677 and earned interest income of \$145, and realized a gain of \$140 on the sale of assets, resulting in a net loss of \$319,078 or \$0.16 per share.

Breakdown of Expenses

	2017	2016
ADMINISTRATION:		
Wages and management fees	\$ 197,485	\$ 219,912
Depreciation	25,335	29,775
Accretion for provision for dismantling	196	117
Professional fees	36,379	24,370
Office expenses	113,083	128,115
Stock based compensation	219,309	-
Directors fees and expenses	11,707	7,569
Travel & entertainment	6,298	32,780
Regulatory fees	11,643	11,369
	\$ 621,435	\$ 456,400
RESEARCH AND DEVELOPMENT:		
Wages and benefits	\$ 352,646	\$ 351,950
Contractors	37,548	62,643
Growing trials	67,369	50,584
Stock based compensation	43,328	-
Rent and utilities	123,696	124,761
Depreciation	43,935	60,241
Other expenses	59,382	68,209
Government assistance	(71,425)	(47,205)
	\$ 656,479	\$ 475,412

**TERRABIOGEN TECHNOLOGIES INC.
MANAGEMENT DISCUSSION AND ANALYSIS
FOR THE YEAR ENDED JUNE 30, 2017**

Liquidity and Capital Resources

During the year ended June 30, 2017, the Company spent \$958,898 (2016 - \$1,046,793) in cash on operating and investing activities, and realized \$996,000 (2016 - \$1,189,352) from financing activities, for a net cash inflow of \$37,102 (2016 - \$142,559), leaving a \$213,957 (2016 - \$176,855) net cash balance at June 30, 2017.

At June 30, 2017, the Company had total liabilities of \$348,469, an increase of \$19,824 from June 30, 2016. The Company had a working capital deficit of \$71,660 compared to a deficit of \$114,500 at June 30, 2016. There are no committed capital expenditures required to meet the Company's planned research and development efforts. The Company signed a new 4 year lease on its premises in Burnaby, expiring on May 31, 2021. Under the new lease, the lease rate changed from the prior rate of \$13.00 per square foot to \$13.50 per square foot in year one and two and \$14.00 per square foot in year three and four. The landlord granted five months of free rent throughout the duration of the new lease. The remaining commitment for rent and operating costs is \$526,831 for the remainder of the four year renewal term; the Company paid a security deposit of \$7,612 which will be applied against the final month's rent.

The Company is dependent on cash from new financing activities and a \$100,000 bank line of credit in order to meet its obligations. Until the Company generates significant sales, it will be relying on new financing and any difficulty in raising new funds from these activities will have a significant impact on the Company's ability to operate. The Company anticipates that it will be able to raise new financing to cover its operating needs through private placements.

Share Capital

As at September 28, 2017, the Company has 2,243,513 common shares issued and outstanding for a total of \$40,478,088 in share capital. The Company closed a non-brokered private placement of 192,000 units at \$3.00 per unit for gross proceeds of \$576,000. Each unit consists of one common share and one warrant exercisable at \$5.00 per share expiring in five years. There are currently 869,125 warrants exercisable into common shares at a weighted average exercise price of \$8.93 and 177,000 stock options exercisable into common shares at a weighted average exercise price of \$5.00.

Off Balance Sheet Arrangements

To the best of management's knowledge, there are no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on the results of operations or financial condition of the Company.

Business Development

The Company's focus has been the development, formulation and launch of its first generation product, TerraBioGen LCFX and its next generation products. The Company has pre-marketed LCFX to select, influential Canadian commercial greenhouse vegetable growers. Based on the results of the pre-market trials, the Company is further improving its formulations to optimize performance and is repeating trials to confirm product formulation efficacy. To support the launch of LCFX, the Company is collaborating with Canada's National Research Council, the University of Guelph, and McMaster University in understanding the mechanism of action of its bioactive materials.

The Company continues to conduct extensive research on its next generation of microbial metabolite bioactive materials through strain development and characterization, process optimization and formulation. The Company is working closely with grower/cooperator partners to ensure that the products are well formulated and effective.

Patents

In September 2016, the Company filed a provisional patent with the US Patent and Trademark Office for its lead strain with claims covering production process and product formulation, and product application and performance on a wide variety of crops. The Company has until the end of September 2017 to file the full patent with the USPTO and PCT. The Company anticipates filing further provisional patents in 2017 and 2018.

**TERRABIOGEN TECHNOLOGIES INC.
MANAGEMENT DISCUSSION AND ANALYSIS
FOR THE YEAR ENDED JUNE 30, 2017**

Transactions with Related Parties

During the year ended June 30, 2017, the Company paid fees of \$4,000 for accounting and financial services to a company controlled by an officer. Also, directors receive a fee of \$200 for each meeting or committee meeting attended; directors' fees of \$11,600 were expensed during the year ended June 30, 2017 and \$9,600 of fees were paid to directors. There were \$5,800 in fees payable to directors at June 30, 2017.

Critical Accounting Estimates and Judgments

The preparation of these consolidated financial statements requires management to make certain critical accounting estimates and assumptions that affect the application of accounting policies and the reported amount of assets, liabilities, income and expenses. It also requires management to exercise judgment in applying the Company's accounting policies. Significant areas requiring the use of management estimates include the fair value measurements for equity instruments. Actual results could differ from those estimates.

Information about assumptions and estimation uncertainties in applying accounting policies that have the most significant effect on the amounts recognized in the consolidated financial statements are included in the following notes:

- Note 11 Share capital – fair value measurements for equity instruments

Information about critical judgments that management has made in applying the Company's accounting policies that have the most significant effect on the amounts recognized in the consolidated financial statements include the going concern assessment, the classification of financial instruments, the applicability of government assistance programs, and the determination of cash generating units for purposes of impairment testing.

Changes in Accounting Policies

New standards and interpretations not yet adopted

The following is an overview of accounting standard changes that the Company will be required to adopt in future years. The Company does not expect to adopt any of these standards before their effective dates. The Company continues to evaluate the impact of these standards on its consolidated financial statements.

(a) IFRS 9 - Financial Instruments:

On July 24, 2014 the IASB issued the complete IFRS 9 (IFRS 9 (2014)).

IFRS 9 (2014) introduces new requirements for the classification and measurement of financial assets. Under IFRS 9 (2014), financial assets are classified and measured based on the business model in which they are held and the characteristics of their contractual cash flows.

The standard introduces additional changes relating to financial liabilities.

It also amends the impairment model by introducing a new 'expected credit loss' model for calculating impairment.

IFRS 9 (2014) also includes a new general hedge accounting standard which aligns hedge accounting more closely with risk management.

The mandatory effective date of IFRS 9 is for annual periods beginning on or after January 1, 2018 and must be applied retrospectively with some exemptions. Early adoption is permitted. The restatement of prior periods is not required and is only permitted if information is available without the use of hindsight.

The Company intends to adopt IFRS 9 (2014) in its financial statements for the annual period beginning on July 1, 2018. The extent of the impact of adoption of the standard has not yet been determined.

TERRABIOGEN TECHNOLOGIES INC.
MANAGEMENT DISCUSSION AND ANALYSIS
FOR THE YEAR ENDED JUNE 30, 2017

(b) IFRS 15 Revenue from Contracts with Customers

On May 28, 2014 the IASB issued IFRS 15 Revenue from Contracts with Customers. The new standard is effective for annual periods beginning on or after January 1, 2017. On July 22, 2015, the IASB deferred the effective date of this standard to January 1, 2018 with earlier adoption permitted. The standard contains a single model that applies to contracts with customers and two approaches to recognizing revenue: at a point in time or over time. The model features a contract-based five-step analysis of transactions to determine whether, how much and when revenue is recognized. New estimates and judgmental thresholds have been introduced, which may affect the amount and/or timing of revenue recognized.

The Company intends to adopt IFRS 15 in its financial statements for the annual period beginning on July 1, 2018. The extent of the impact of adoption of the standard has not yet been determined.

(c) IFRS 16 Leases

In January 2016, the IASB issued IFRS 16 – Leases, which supersedes IAS 17 – Leases. IFRS 16 establishes principles for the recognition, measurements presentation and disclosure of leases. The standard establishes a single model for lessees to bring leases on balance sheet while lessor accounting remains largely unchanged and retains the finance and operation lease distinctions. IFRS 16 is effective for annual periods beginning on or after January 1, 2019 with earlier adoption permitted, but only if also applying IFRS 15 – Revenue from Contracts with Customers.

Financial Instruments

The Company's financial instruments consist of cash, amounts receivable and accounts payables and accrued liabilities. The fair values of these financial instruments approximate carrying value because of their short-term nature. Cash and government grants receivable are classified as loans and receivables, which are measured at amortized cost. Accounts payable, accrued liabilities and customer deposits are classified as other financial liabilities and are measured at amortized cost.

The Company's risk exposures and the impact on the Company's financial instruments are summarized below:

Foreign exchange risk

Most of the Company's operating expenditures are denominated in Canadian dollars and certain operating expenses are in United States dollars. The Company's exposure to foreign currency risk arises primarily on fluctuations between the Canadian dollar and the United States dollar.

The Company has not entered into any derivative instruments to manage foreign exchange fluctuations.

At June 30, 2017 and June 30, 2016, a change of 10% +/- in the US dollar would not result in a significant impact in the statements of loss and comprehensive loss.

Interest rate risk

The Company is subject to interest on its bank loans which are at negotiated rates of interest. Significant increase in these interest rates would result in increased costs for the Company.

Credit risk

Credit risk is the risk of an unexpected loss if a counterparty to a financial instrument fails to meet its contractual obligations. The credit risk associated with cash is believed to be minimal as cash is on deposit with Canadian banks that are believed to be creditworthy. Amounts receivable is comprised primarily of amounts due from the Government of Canada. The Company does not believe it is exposed to significant credit risk.

**TERRABIOGEN TECHNOLOGIES INC.
MANAGEMENT DISCUSSION AND ANALYSIS
FOR THE YEAR ENDED JUNE 30, 2017**

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company manages liquidity risk through the management of its capital structure and financial leverage as outlined above.

The Company monitors its ability to meet its short-term operating expenditures by raising additional funds through share issuance when required. All of the Company's financial liabilities have contractual maturities of 30 days or are subject to normal trade terms.

Reclassifications

Certain comparative figures have been reclassified to conform with the financial statement presentation adopted for the current year.

Additional Information

Additional information about TerraBioGen Technologies Inc. can be found on SEDAR at www.sedar.com or on the Company's website at www.TerraBioGen.com.